IceCure director Huang Yang reports equity holdings

IceCure Medical Ltd. director Huang Yang filed an initial ownership report detailing equity holdings in the company.

Rhea-AI Filing Summary

IceCure Medical Ltd. director Huang Yang filed an initial ownership report detailing equity holdings in the company. The filing shows 111,468 restricted stock units (RSUs) granted on May 15, 2025, with 41,800 vested and 69,668 unvested as of March 18, 2026.

Huang also holds several fully vested share options over ordinary shares, including 25,000 options at an exercise price of $1.70 per share expiring in December 2030 and 80,668 options at $3.64 per share expiring in January 2032, plus an additional option grant at $1.51 per share expiring in February 2033.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Huang Yang

Role Director

Type	Security	Shares	Price	Value
holding	Share option (right to buy)	--	--	--
holding	Share option (right to buy)	--	--	--
holding	Share option (right to buy)	--	--	--
holding	Ordinary shares	--	--	--

Holdings After Transaction: Share option (right to buy) — 146,373 contracts (Direct); Ordinary shares — 111,468 shares (Direct)

Footnotes (7)

1. F1. Represents 111,468 RSUs granted on May 15, 2025, 25% of which vested on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 41,800 RSUs have vested and 69,668 remain unvested as of March 18, 2026.
2. F2. The options were granted on December 13, 2020, 25% of which vested on December 13, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 25,000 options are fully vested.
3. F3. The options were granted with an exercise price of NIS 5.256 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.70 per share.
4. F4. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested.
5. F5. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.
6. F6. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 30,528 options are fully vested.
7. F7. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Huang Yang’s Form 3 for IceCure Medical (ICCM) disclose?

The Form 3 discloses Huang Yang’s existing equity holdings in IceCure Medical, including ordinary shares represented by RSUs and multiple series of fully vested share options with specified exercise prices and expiration dates, as of March 18, 2026.

How many RSUs does Huang Yang hold in IceCure Medical (ICCM)?

Huang Yang holds 111,468 RSUs granted on May 15, 2025. As of March 18, 2026, 41,800 RSUs have vested and 69,668 remain unvested, vesting in equal quarterly installments of 6.25% after the initial 25% vesting.

What share options are reported for Huang Yang in IceCure Medical (ICCM)?

The filing lists fully vested options over ordinary shares, including 25,000 options at $1.70 per share expiring December 13, 2030, and 80,668 options at $3.64 per share expiring January 12, 2032, plus an additional grant at $1.51 per share expiring February 19, 2033.

Were Huang Yang’s options in IceCure Medical (ICCM) already vested?

Yes. Footnotes state the options granted in December 2020 and January 2022 are fully vested as of March 18, 2026. Another option grant from February 2023 is also described as fully vested by that date, following standard quarterly vesting after the initial 25%.

Does Huang Yang’s Form 3 for IceCure Medical (ICCM) show any recent share purchases or sales?

No new purchases or sales are indicated. The entries are classified as holdings, with transaction codes and directions marked as unknown and net buy/sell activity shown as neutral, meaning the form mainly records existing positions rather than fresh market transactions.

What currencies and exchange rates are used for Huang Yang’s IceCure Medical (ICCM) options?

The options were originally granted with exercise prices in New Israeli Shekels. For disclosure, prices were converted using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in exercise prices of $1.70, $3.64, and $1.51 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Huang Yang

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	111,468(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)	(2)	12/13/2030	Ordinary shares	25,000	$1.7(3)	D
Share option (right to buy)	(4)	01/12/2032	Ordinary shares	80,668	$3.64(5)	D
Share option (right to buy)	(6)	02/19/2033	Ordinary shares	40,705	$1.51(7)	D

Explanation of Responses:

1. Represents 111,468 RSUs granted on May 15, 2025, 25% of which vested on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 41,800 RSUs have vested and 69,668 remain unvested as of March 18, 2026.

2. The options were granted on December 13, 2020, 25% of which vested on December 13, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 25,000 options are fully vested.

3. The options were granted with an exercise price of NIS 5.256 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.70 per share.

4. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 80,668 options are fully vested.

5. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.

6. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 30,528 options are fully vested.

7. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.

	/s/ Yang Huang	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)